DiagnosticIn Clinical Trials

Bombesin Analog Tracers

Intravenous

Overview

Bombesin analog tracers are synthetic peptides based on the 14-amino acid amphibian peptide bombesin or its mammalian counterpart gastrin-releasing peptide (GRP), radiolabeled for molecular imaging. These analogs bind to GRP receptors, which are overexpressed in prostate, breast, and small cell lung cancers, enabling tumor visualization via PET or SPECT imaging.

Mechanism of Action

Various radionuclides including gallium-68, fluorine-18, technetium-99m, and copper-64 have been conjugated to bombesin antagonist and agonist peptides..

Research Summary & Key Findings

Phase 1 and Phase 2 clinical trials have evaluated multiple bombesin analogs including 68Ga-RM2, 68Ga-SB3, and 99mTc-DB4 for imaging prostate cancer and breast cancer, with results published in the Journal of Nuclear Medicine and European Journal of Nuclear Medicine between 2007 and 2020. While these agents demonstrate receptor-specific tumor uptake and acceptable safety, none have achieved regulatory approval, largely due to competition from PSMA-targeted tracers in prostate cancer imaging.

Clinical Status

In Clinical Trials

Bombesin Analog Tracers is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Intravenous

Related Peptides in Diagnostic

Find a Provider

Find a verified provider who offers Bombesin Analog Tracers therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Bombesin Analog Tracers.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.